{"url_path":"/sec/mbx/8-k/2026-06-05/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1776111/0001193125-26-258417-index.html","accession_number":"0001193125-26-258417","cik":"0001776111","ticker":"MBX","issuer_name":"MBX Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1776111/0001193125-26-258417-index.html","primary_entity_key":"0001776111","primary_entity_name":"MBX Biosciences, Inc."},"word_count":292,"has_tables":true,"body_markdown":"## Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nThe Company held its Annual Meeting on June 4, 2026. As of April 10, 2026, the record date for the Annual Meeting, there were 47,570,485 shares outstanding shares of the Company's common stock. The Company's stockholders voted on the following matters, which are described in detail in the Proxy Statement: (i) to elect two Class II director nominees, Patrick J. Heron. and Edward T. Mathers, to the Company's Board of Directors, each to hold office until the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal (\"Proposal 1\") and (ii) to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 (\"Proposal 2\").\n\n \n\nThe Company's stockholders approved the Class II director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company's stockholders voted for Class I directors as follows:\n\n \n\nClass II Director Nominee\n\n \n\nFor\n\n \n\nWithhold\n\n \n\nBroker Non-Votes\n\n \n\nPatrick J. Heron\n\n \n\n35,007,623\n\n \n\n4,579,129\n\n \n\n4,130,833\n\n \n\nEdward T. Mathers\n\n \n\n31,983,223\n\n \n\n7,603,529\n\n \n\n4,130,833\n\n \n\n \n\nThe Company's stockholders approved Proposal 2 to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes cast at the Annual Meeting were as follows:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n \n\n43,713,693\n\n \n\n1,946\n\n \n\n1,946\n\n \n\n-\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nMBX Biosciences, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 5, 2026\n\nBy:\n\n/s/ P. Kent Hawryluk\n\n \n\n \n\n \n\nPresident and Chief Executive Officer (Principal Executive Officer)"}